Anthem Biosciences to attend investor meets in June 2026

Anthem Biosciences Limited has disclosed its schedule for upcoming analyst and institutional investor meets in June 2026. The management will participate in the Nomura Investment Forum Asia 2026 and the Citi India Conference 2026 to engage with investors.

Conference Schedule

The company outlined the specific dates, locations, and meeting formats for the two events. The schedule includes sessions in Singapore and Mumbai, featuring both one-on-one and group meetings.

Date	Name of the Event	Location	Meeting Type
2nd & 3rd June, 2026	Nomura Investment Forum Asia 2026	Singapore	One on One & Group Meeting
4th & 5th June, 2026	Citi India Conference 2026	Mumbai	One on One & Group Meeting

Disclosure Details

The company stated that no unpublished price-sensitive information (UPSI) will be shared during these meetings. Anthem Biosciences also noted that any unforeseen exigency on the part of the company or the host could lead to changes in the dates or times of the scheduled interactions.

The intimation regarding this participation has been made available on the company's official website.

Anthem Biosciences Limited has announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported its highest revenue quarter ever in Q4FY26, driven by strong performance across its CRDMO and Specialty Ingredients segments.

Q4FY26 Financial Performance

For the quarter ended March 31, 2026, the company reported Revenue from Operations of ₹6,109 Mn, a growth of 26.4% compared to ₹4,832 Mn in the same period last year. On a sequential basis, revenue grew 44.4% from ₹4,232 Mn in Q3FY26. The CRDMO segment contributed ₹5,128 Mn, while Specialty Ingredients contributed ₹981 Mn. Profit After Tax (PAT) for the quarter surged 129.8% to ₹1,898 Mn from ₹826 Mn in Q4FY25. EBITDA stood at ₹3,184 Mn, with margins expanding to 48.1% from 40.38% in the same period last year.

The following table summarises Anthem Biosciences' key financial metrics for Q4FY26:

Metric (₹ Mn)	Q4FY26	Q4FY25	YoY Growth
Revenue from Operations	6,109	4,832	26.4%
EBITDA	3,184	2,092	52.2%
EBITDA Margin	48.1%	40.38%	—
Profit After Tax	1,898	826	129.8%

FY26 Annual Results

For the full financial year 2025-26, Revenue from Operations grew 15.2% to ₹21,243 Mn from ₹18,446 Mn in FY25. The CRDMO business recorded revenues of ₹17,727 Mn, and Specialty Ingredients recorded ₹3,516 Mn. PAT for the year increased 31.1% to ₹5,918 Mn, while EBITDA grew 30.8% to ₹9,896 Mn. The company maintained a healthy net cash position of ₹13,743 Mn as of March 31, 2026.

Metric (₹ Mn)	FY26	FY25	YoY Growth
Revenue from Operations	21,243	18,446	15.2%
EBITDA	9,896	7,566	30.8%
Profit After Tax	5,918	4,513	31.1%
Net Cash Position	13,743	—	—

Operational Highlights

The company's EBITDA and PAT for the year grew by more than 30%, in line with its growth aspirations. Management attributed the performance to prudent cost management and a focus on long-term value creation. Profit before tax before exceptional items for FY26 stood at ₹8,486 Mn, with an exceptional item of ₹244 Mn recognized regarding the impact of new labour codes. For Q4FY26, the exceptional item was a credit of ₹10 Mn.

Anthem Biosciences continues to invest in expanding its manufacturing capacity, including a new greenfield facility at Harohalli, Bangalore, with a Phase I investment of ₹12,000 Mn. The company will conduct an earnings call on May 20, 2026, at 11:00 am IST to discuss the financial and business performance.